June 18, 2020
Hill Dermaceuticals, Inc., a privately-held pharmaceutical company based in Sanford, Florida at the Orlando-Sanford Airport, which develops, manufactures and distributes specialty prescription dermatology products, is pleased to announce that Tolak® (fluorouracil) 4% Cream, has been successfully registered in the United Kingdom and in 13 countries within Europe, including France, Germany, Spain, Italy, Belgium, Sweden, Norway, […]
August 17, 2018
Hill has remained true to its commitment to dermatology and skin health. The foundation of Hill’s prescription dermatology products are its vehicles, also known as product base formulations without any active medication ingredients. Our vehicles contain refined peanut oil and have been shown to keep moisture in the skin, supporting the effectiveness of Hill’s prescription […]
June 4, 2018
You might be wondering why we use refined peanut oil in many of our products. The reason is that refined peanut oil contains two essential fatty acids — linoleic acid and alpha-linolenic acid — which have been shown to (1) improve the skin’s barrier functionality and (2) help maintain appropriate hydration of the skin1,2. Typically, […]
March 3, 2017
* TOLAK is a patented prescription dermatologic drug developed by Hill Dermaceuticals for the topical treatment of actinic keratosis, a skin disease with increasing prevalence worldwide due to the combined effect of sun damage and population aging. * Pierre Fabre, a leading pharmaceutical company in dermatology, acquired commercialization rights for TOLAK in the USA and […]
January 9, 2017
Sanford, Florida, January 09, 2017 – Hill Dermaceuticals, Inc®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced the opening of its second location. Hill’s new facility houses both offices, and alternate manufacturing suites for future projects.
May 22, 2014
Sanford, Florida, May 22, 2014 – Hill Dermaceuticals, Inc®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to its investigational drug for Fungal Otitis Externa (Otomycosis).